title: A Protective Role for Androgen Receptor in Clear Cell Renal Cell Carcinoma Based on Mining TCGA Data.
abstract: Androgen receptor (AR) is expressed in normal murine and human kidneys of both genders, but its physiologic role is uncertain. Several studies showed loss of AR in renal cell carcinoma (RCC) in conjunction with increasing clinical stage and pathological grade, but others found that higher AR expression correlated with worse outcomes. Limited functional studies with renal cell lines suggested tumor-promoting activity of AR. In this study, we queried transcriptomic, proteomic, epigenetic and survival data from The Cancer Genome Atlas (TCGA) to evaluate AR expression and its association with overall survival in three subtypes of RCC (clear cell [ccRCC], papillary [pRCC], and chromophobe [chRCC]). We found that although there was no significant difference in AR mRNA expression in ccRCC of males vs. females, AR protein expression in ccRCC was significantly higher in male compared to female patients. More importantly, higher expression of AR at both transcript and protein levels was associated with improved overall survival in both genders with ccRCC, but did not predict survival of either gender with pRCC or chRCC. Genes whose transcript levels were associated with AR mRNA levels significantly overlapped between ccRCC and pRCC, but not with chRCC, suggesting a similar transcriptional program mediated by AR in ccRCC and pRCC. Ingenuity pathway analysis also identified overlapping pathways and upstream regulators enriched in AR-associated genes in ccRCC and pRCC. Hypermethylation of CpG sites located in the promoter and first exon of AR was associated with loss of AR expression and poor overall survival. Our findings support a tumor suppressor role for AR in both genders that might be exploited to decrease the incidence or progression of ccRCC.
authors.affiliation: Department of Urology, Stanford University School of Medicine, Stanford, California, United States of America.
authors.forename: Hongjuan
authors.initials: H
authors.lastname: Zhao
authors.affiliation: Department of Urology, Stanford University School of Medicine, Stanford, California, United States of America.|Veterans Affairs Palo Alto Health Care System, Palo Alto, California, United States of America.
authors.forename: John T
authors.initials: JT
authors.lastname: Leppert
authors.affiliation: Department of Urology, Stanford University School of Medicine, Stanford, California, United States of America.
authors.forename: Donna M
authors.initials: DM
authors.lastname: Peehl
mesh_terms: D002291:Carcinoma, Papillary / Q000378:metabolism / Q000401:mortality / Q000473:pathology*; D002292:Carcinoma, Renal Cell / Q000378:metabolism / Q000401:mortality / Q000473:pathology*; D016000:Cluster Analysis; D015331:Cohort Studies; D018899:CpG Islands; D019175:DNA Methylation; D030541:Databases, Genetic; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D007680:Kidney Neoplasms / Q000378:metabolism / Q000401:mortality / Q000473:pathology*; D008297:Male; D011379:Prognosis; D011401:Promoter Regions, Genetic; D012333:RNA, Messenger / Q000378:metabolism; D012334:RNA, Neoplasm / Q000737:chemistry / Q000378:metabolism; D011944:Receptors, Androgen / Q000235:genetics / Q000378:metabolism*; D017423:Sequence Analysis, RNA; D012737:Sex Factors
chemical_list: C410798:AR protein, human; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D011944:Receptors, Androgen
references.citation: Cancer Res. 2014 Jan 15;74(2):543-51
references.pmid: 24253377
references.citation: Exp Cell Res. 2015 Feb 1;331(1):239-50
references.pmid: 25447311
references.citation: Cancer Cell. 2014 Sep 8;26(3):319-30
references.pmid: 25155756
references.citation: Int Urol Nephrol. 2015 Jan;47(1):81-5
references.pmid: 25218615
references.citation: J Urol. 2004 Feb;171(2 Pt 1):611-4
references.pmid: 14713771
references.citation: Mol Cancer Ther. 2015 Apr;14(4):1066-74
references.pmid: 25637315
references.citation: Biochem Biophys Res Commun. 2002 Jun 21;294(4):779-84
references.pmid: 12061774
references.citation: Cancer Res. 2014 Aug 15;74(16):4420-30
references.pmid: 24924778
references.citation: Endocrinology. 1974 Mar;94(3):746-56
references.pmid: 4360476
references.citation: Genome Med. 2014 Dec 11;6(12):117
references.pmid: 25648588
references.citation: EMBO J. 2014 Feb 18;33(4):312-26
references.pmid: 24451200
references.citation: Urol Oncol. 2014 Jan;32(1):43.e23-30
references.pmid: 23911681
references.citation: Eur J Cancer. 1993;29A(7):997-9
references.pmid: 8499154
references.citation: Urol Oncol. 2013 Oct;31(7):1316-20
references.pmid: 22264501
references.citation: J Urol. 2015 Nov;194(5):1441-8
references.pmid: 25796113
references.citation: J Urol. 2014 Jun;191(6):1665-70
references.pmid: 24423441
references.citation: Clin Cancer Res. 2013 Oct 1;19(19):5505-12
references.pmid: 23965901
references.citation: Nat Rev Urol. 2014 Aug;11(8):425
references.pmid: 24980195
references.citation: Tumour Biol. 2014 Jan;35(1):1-7
references.pmid: 23943393
references.citation: Hypertension. 2005 Oct;46(4):787-98
references.pmid: 16172422
references.citation: BMC Cancer. 2010;10:315
references.pmid: 20569440
references.citation: Nephrol Dial Transplant. 2014 Aug;29(8):1475-80
references.pmid: 24516223
references.citation: Eur Urol. 2015 Jan;67(1):85-97
references.pmid: 24857407
references.citation: Nat Rev Urol. 2010 May;7(5):245-57
references.pmid: 20448658
references.citation: Mod Pathol. 1998 Jan;11(1):55-9
references.pmid: 9556423
references.citation: Mod Pathol. 2010 Feb;23(2):205-12
references.pmid: 19898421
references.citation: Recent Prog Horm Res. 1986;42:71-109
references.pmid: 3526457
references.citation: PLoS One. 2015;10(9):e0139267
references.pmid: 26406598
references.citation: J Am Soc Nephrol. 2011 Apr;22(4):598-604
references.pmid: 21436284
references.citation: Curr Opin Nephrol Hypertens. 2013 Jul;22(4):439-44
references.pmid: 23666414
references.citation: Urology. 2014 Feb;83(2):510.e19-24
references.pmid: 24332122
references.citation: J Am Soc Nephrol. 2014 Jul;25(7):1430-9
references.pmid: 24652800
references.citation: Pathology. 2013 Oct;45(6):574-80
references.pmid: 24018803
references.citation: Mol Cancer Ther. 2015 Mar;14(3):769-78
references.pmid: 25713333
references.citation: Nat Rev Urol. 2014 Nov;11(11):614-6
references.pmid: 25287783